Genitourinary Cancers | Specialty

First-Line Considerations in Metastatic Renal Cell Carcinoma

December 19th 2015

Advanced Prostate Cancer Clinics Make Inroads in Practices

December 15th 2015

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Dr. Petrylak on Atezolizumab in Bladder Cancer

December 15th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

UC Davis Meets NCI-Designation With Great Responsibility

November 30th 2015

Conference Highlights, Three FDA Approvals, and More

November 30th 2015

Personalized Peptide Vaccination Increased Survival in Advanced Bladder Cancer

November 28th 2015

The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.

FDA Approves Nivolumab for Metastatic Renal Cell Carcinoma

November 23rd 2015

The FDA has approved nivolumab as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

Checkpoint Inhibitors Generate Renewed Excitement in RCC

November 18th 2015

With several novel therapies approaching regulatory approval, the treatment landscape for renal cell carcinoma is facing a major upheaval.

FDA Panel Rejects Immunotherapy MCNA in Bladder Cancer

November 18th 2015

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

FDA Grants Priority Review to Nivolumab for Renal Cell Carcinoma

November 16th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for patients with advanced renal cell carcinoma following prior antiangiogenic therapy.

Promising Immunotherapy Agents on Horizon in Bladder Cancer

November 16th 2015

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

Experts Discuss Exciting Novel Therapies, Challenges in RCC

November 11th 2015

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.

Dr. Figlin on Sunitinib for Patients With RCC

November 9th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 4th 2015

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

LUGPA Meeting Focuses on Business and Clinical Challenges

November 4th 2015

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer

November 3rd 2015

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Dr. Richards on Unanswered Questions in Treating Bladder Cancer

November 3rd 2015

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Motzer Discusses Nivolumab's Survival, QoL Benefits in RCC

November 2nd 2015

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Petrylak Highlights Potential of PD-1/PD-L1 Inhibitors in Bladder Cancer

October 29th 2015

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

FDA Approval Sought for Cabozantinib in Advanced RCC

October 23rd 2015

Rolling submission of a new drug application for cabozantinib has been initiated for patients with advanced renal cell carcinoma who have received one prior therapy.